miR-338-3p Replenishment for Schizophrenia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for schizophrenia and 22q11 deletion syndrome, particularly positive symptoms like hallucinations and delusions, are inadequate due to side effects and limited understanding of the underlying neuronal mechanisms, especially regarding the delayed onset of psychotic symptoms.
Innovation Solution
Replenishing miR-338-3p in thalamic neurons using miR-338-3p or its mimics, or vectors expressing miR-338-3p, to normalize Drd2 levels and reduce antipsychotic sensitivity, thereby addressing the pathogenic mechanisms underlying these conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antipsychotics are used to treat positive symptoms of schizophrenia, then positive symptoms are alleviated, but multiple devastating side effects occur including blood abnormalities, weight gain, and abnormal movements
Solution Approach 1:
The patent introduces miR-338-3p as an intermediary molecule that mediates the therapeutic effect. Instead of directly blocking dopamine receptors with antipsychotics, the invention uses miR-338-3p to regulate Drd2 expression levels, thereby indirectly modulating dopamine signaling. This intermediary approach achieves symptom relief while avoiding the direct receptor blockade that causes severe side effects
Solution Approach 2:
The invention changes the therapeutic parameter from direct receptor inhibition (antipsychotic drugs) to post-transcriptional regulation of receptor expression (miR-338-3p). By altering the level of Drd2 expression through miRNA regulation rather than blocking existing receptors, the treatment achieves similar therapeutic outcomes with dramatically reduced side effects
2Reliability
If systemic inhibition of DRD2 is used to alleviate positive symptoms, then positive symptoms improve, but cognitive and negative symptoms are not treated
Solution Approach 1:
The patent applies local quality by delivering miR-338-3p specifically to thalamic neurons rather than systemically. The invention uses targeted delivery mechanisms (such as adeno-associated virus vectors or lipid nanoparticles) to concentrate the therapeutic agent in the thalamus, where it can selectively regulate Drd2 expression in thalamocortical projection neurons. This localized approach allows precise modulation of specific neural circuits involved in schizophrenia pathology while preserving other brain functions
Solution Approach 2:
The invention segments the treatment approach by targeting specific neural circuits (thalamocortical projections) rather than globally inhibiting dopamine receptors throughout the brain. By dividing the therapeutic action into circuit-specific modulation, the treatment can address multiple symptom domains (positive, cognitive, and negative symptoms) that arise from dysregulation in specific thalamic circuits
3Reliability
If miR-338-3p is replenished in thalamic neurons, then Drd2 levels are normalized and antipsychotic sensitivity is reduced, but the mechanism of delayed onset of psychotic symptoms remains to be fully understood
Solution Approach 1:
The patent incorporates feedback mechanisms by monitoring Drd2 expression levels and miR-338-3p activity to adjust treatment dosage and timing. The invention uses biomarker assessment (such as measuring Drd2 mRNA levels or functional dopamine receptor assays) to determine when therapeutic effects are achieved, allowing dynamic adjustment of the treatment regimen to optimize outcomes while minimizing side effects
Data Source
AI summary
The invention is directed to a method for treating the 22q11 deletion syndrome (22q11 DS) and schizophrenia (SCZ) by replenishment of decreased levels of miR-338-3p in thalamic neurons.